Orexigen Therapeutics, Inc.

Eli Lilly and Company

Nalpropion Pharmaceuticals LLC

Gary Dennis Tollefson

Anthony A McKinney

Eckard Weber

Rick Soltero

Richard Soltero

Eduardo Dunayevich

Michael Alexander Cowley

John Harrison Heiligenstein

Thea Elise Dunzo

Franklin P Bymaster

Steven Marc Paul

Kurt Rasmussen

Bennett C Laguzza

Charles M Beasley, Jr

Kenneth Wayne Perry

Anthony A Mckinney

Ron Vladyka

Simon Yau

Methods and systems for administration of pharmaceuticals using a unit dosage package that includes a first unit dosage that has a first drug and a second drug, a second unit dosage that has the first drug and the second drug, where the second unit dosage includes a different amount of the second drug than the first unit dosage and a unit dosage package is configured to hold the first unit dosage and the second unit dosage. In preferred embodiments the methods and systems are used for administration of weight loss medications.

Methods for administering weight loss medications

Disclosed are methods and compositions for treating visceral fat conditions and/or metabolic syndrome using combinations of naltrexone and bupropion.

Methods for treating visceral fat conditions

Disclosed are methods of providing weight loss therapy, particularly for patients suffering from major depression.

Methods of providing weight loss therapy in patients with major depression

Methods and compositions for treating a blood glucose condition involve identifying a suitable subject and administering an effective amount of a composition that contains one or more of an opioid antagonist, an anticonvulsant, and a psychotherapeutic agent. The compositions can include insulin. In some embodiments, such methods and compositions can be used to modulate a blood glucose level. In preferred embodiments, such methods and compositions are useful for increasing a subject's sensitivity to insulin.

Compositions and methods for increasing insulin sensitivity

A sustained-release oral dosage form of naltrexone or a pharmaceutically acceptable salt thereof is provided. The oral dosage form may be administered with another compound. Administration of the oral dosage form may reduce a side effect, which may be a side effect at least partially attributable to a weight-loss treatment. The oral dosage form may be administered to treat a weight-loss condition.

Sustained release formulation of naltrexone

In one embodiment a layered pharmaceutical formulation includes two or more pharmaceutical layers and an intermediate layer disposed between at least two of the two or more pharmaceutical layers, the intermediate layer configured to dissolve in vivo to thereby leave the two or more pharmaceutical layers substantially intact. In one embodiment, an active pharmaceutical ingredient in at least one of the pharmaceutical layers is selected from bupropion, zonisamide, naltrexone, topiramate, phentermine, metformin, olanzapine and fluoxetine.

Layered pharmaceutical formulations

Methods for treating a patient suffering from or susceptible to treatment resistant major depression comprising administering olanzapine and fluoxetine are disclosed.

Combination therapy for treatment of refractory depression

Growing community of inventors

Indianapolis, IN, United States of America

Gary Dennis Tollefson